Clinical trial
A Phase II Study Evaluating RNS60 Compared to Interferon Beta-1a (Avonex) for the Treatment of Relapsing Remitting Multiple Sclerosis
NCT01714089 is registered in ClinicalTrials.gov with Revalesio Corporation as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase II Study Evaluating RNS60 Compared to Interferon Beta-1a (Avonex) for the Treatment of Relapsing Remitting Multiple Sclerosis
- Lead sponsor
- Revalesio Corporation
- Phase
- Phase 2
- Overall status
- Withdrawn
- Start date
- Not reported
- Completion date
- Not reported
- Enrollment
- 0 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
relapsing remitting multiple sclerosis